Herceptin-LCN2-targeted siRNA

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameHerceptin-LCN2-targeted siRNA

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody-Oligonucleotide conjugate > Antibody-siRNA conjugate

Mechanisms of ActionNeutrophil gelatinase-associated lipocalin inhibitors

TargetsNeutrophil gelatinase-associated lipocalin

Therapy Area/IndicationsInflammatory Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Puerto Rico

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Puerto Rico

Inactive CompaniesN/A

Active IndicationsInflammatory Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A